Department of Neurology, Postgraduate Institute of Medical and Research, Chandigarh, India.
Indian J Pharmacol. 2020 Jan-Feb;52(1):49-52. doi: 10.4103/ijp.IJP_333_18. Epub 2020 Mar 11.
Approximately 10%-15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to conventional treatment. We report six patients with refractory MuSK-positive MG who responded well to the treatment with rituximab.
In this prospective institute-based observational study, we report six MuSK antibody-positive MG patients, who did not achieve remission with standard treatment and were later started on rituximab infusion.
There was a significant clinical improvement in all patients after starting rituximab.
Rituximab is an effective immunomodulatory therapy in MuSK antibody-positive MG patients who are not responding to the standard treatment.
约 10%-15%的重症肌无力 (MG) 患者对标准治疗无反应。这些患者中有相当一部分是由于肌肉特异性酪氨酸激酶 (MuSK) 抗体阳性 MG 引起的，这种疾病通常病情严重，频繁复发，对常规治疗反应不佳。我们报告了 6 例对标准治疗无反应的 MuSK 阳性 MG 患者，他们对利妥昔单抗治疗反应良好。
在这项前瞻性的基于机构的观察性研究中，我们报告了 6 例 MuSK 抗体阳性 MG 患者，他们在标准治疗后未达到缓解，并随后开始利妥昔单抗输注。
所有患者在开始利妥昔单抗治疗后均有显著的临床改善。
利妥昔单抗是 MuSK 抗体阳性 MG 患者的一种有效免疫调节治疗方法，这些患者对标准治疗无反应。
